Trial · NCT00588536
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
NCT00588536, Phase 2, Completed, Memorial Sloan Kettering Cancer Center; results first posted 2015-05-04
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH. Trials, record NCT00588536. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00588536
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
- NCT number
- NCT00588536
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Conditions
- Langerhans Cell Histiocytosis
- Interventions
- Methotrexate, 6-Thioguanine, Leucovorin Calcium
- First posted
- 2008-01-08
- Last updated
- 2015-05-04
- Results first posted
- 2015-05-04
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. | Conclusion of the study |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. | Conclusion of the study | participants | NUMBER |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. | MTX, 6-TG and Leucovorin | Complete Response | 2 | participants | |
Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. | MTX, 6-TG and Leucovorin | Stable Disease | 1 | participants | |
Determine the Incidence of Complete and Partial Response and the Duration of Response in Patients With Langerhans Cell Histiocytosis (LCH) Treated With Sequential Administration of Oral 6-TG After MTX. | MTX, 6-TG and Leucovorin | Progression of Disease | 2 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MTX, 6-TG and Leucovorin | 5 | |
| Overall Study | COMPLETED | MTX, 6-TG and Leucovorin | 5 | |
| Overall Study | NOT COMPLETED | MTX, 6-TG and Leucovorin | 0 |
Source ClinicalTrials.gov
Adverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal pain/cramping | Gastrointestinal disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Anorexia | Metabolism and nutrition disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Blood bilirubin increased | Investigations | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Bone pain | Musculoskeletal and connective tissue disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Sore throat | Respiratory, thoracic and mediastinal disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 2 |
| other | Creatinine increased | Investigations | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Diarrhea | Gastrointestinal disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Headache | Nervous system disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
| other | Anemia | Blood and lymphatic system disorders | MTX, 6-TG and Leucovorin | 4 | 5 | 10 |
| other | Hypomagnesemia | Metabolism and nutrition disorders | MTX, 6-TG and Leucovorin | 1 | 5 | 1 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MTX, 6-TG and Leucovorin | ||
| Total, other adverse events | MTX, 6-TG and Leucovorin | 5 | 5 |
| Total, serious adverse events | MTX, 6-TG and Leucovorin | 2 | 5 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00588536
GET https://conductscience.org/api/trials/v1/NCT00588536/registered